SELLAS Life Sciences Group, Inc. SLS
At closeNov 3, 2026, 6:27 PM EST
After hours · Nov 3, 6:27 PM ET
- YTD
- +135.28%
- 1 year
- +395.53%
- Market cap
- 1.79B
- EPS (ttm)
- -0.21
- Shares out
- 201.95M
- Forward P/E
- -88.70
- YTD return
- +135.28%
- 1-year return
- +395.53%
- Volume
- 5.02M
- Avg volume
- 6.79M
- Open
- 8.72
- Previous close
- 8.55
- Day's range
- 8.57 – 9.18
- 52-week range
- 1.39 – 15.88
- Beta
- 2.70
- Analysts
- Strong Buy
- Price target
- 32.50 (+266.4%)
- Earnings date
- Nov 18, 2026
1Y +7.21 (+434.34%)
Key statistics
- Enterprise value
- 1.59B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 13.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -16.38M
- Total cash
- 138.34M
- Total debt
- 737.00K
- Return on equity
- -39.63%
- Short % of float
- 26.73%
- 50-day average
- 12.02
- 200-day average
- 8.60
Analyst view
Consensus: strong buy
- Target (low)
- 30.00
- Target (mean)
- 32.50
- Target (high)
- 35.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 18, 2026
Expected Nov 18, 2026. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2026 | Sep 30, 2026 | -0.05 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.045 | -0.05 | -0.01 | -11.11% |
| May 12, 2026 | Mar 31, 2026 | -0.06 | -0.05 | +0.01 | +16.67% |
| Mar 19, 2026 | Dec 31, 2025 | -0.06333 | -0.05 | +0.01 | +21.05% |
| Nov 12, 2025 | Sep 30, 2025 | -0.06333 | -0.06 | 0.00 | +5.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.08333 | -0.07 | +0.01 | +16.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | main | Buy | Buy |
| Jul 16, 2025 | Maxim Group | main | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | main | — | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | main | — | Overweight |
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sellaslifesciences.com
News
10 Health Care Stocks Whale Activity In Today’s Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
SELLAS Life Sciences Stock Stumbles: What's Going On? 
SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event 
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia 
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened 
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study 
10 Health Care Stocks With Whale Alerts In Today’s Session 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Your note
Sign in to keep a note on SLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS JOHN THOMAS | Chief Financial Officer | Stock Award(Grant) | Jan 6, 2026 | 554,327 |
| CICIC DRAGAN | Officer | Stock Award(Grant) | Jan 6, 2026 | 557,805 |
| KALIN KATHERINE BACH | Director | Stock Award(Grant) | Jan 6, 2026 | 154,400 |
| SCHEINBERG DAVID A | Director | Stock Award(Grant) | Jan 6, 2026 | 73,082 |
| STERGIOU ANGELOS M | Chief Executive Officer | Stock Award(Grant) | Jun 15, 2026 | 1,759,180 |
| VAN NOSTRAND ROBERT L | Director | Stock Award(Grant) | Jan 6, 2026 | 82,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.46% | 15,070,302 | 133.67M | Jun 29, 2026 |
| State Street Corporation | 6.44% | 12,996,558 | 115.28M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.07% | 8,226,105 | 72.97M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.42% | 4,884,175 | 43.32M | Jun 29, 2026 |
| Anson Funds Management LP | 2.23% | 4,500,000 | 39.91M | Jun 29, 2026 |
| Jones Financial Companies, L.L.L.P. | 1.14% | 2,304,561 | 20.44M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 5,906,922 | 52.39M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.81% | 5,665,912 | 50.26M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 5,214,545 | 46.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 2,134,837 | 18.94M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 2,067,019 | 18.33M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.93% | 1,880,069 | 16.68M | Sep 29, 2026 |